Stock picks by Sameet Chavan: Buy Strides Pharma, sell Grasim

We finally witnessed a decisive price and volume breakout from the recent congestion zone in Strides Pharma

Buy, Sell, markets, stocks, shares, investments, mutual funds, investors
Sameet Chavan New Delhi
4 min read Last Updated : Apr 19 2021 | 8:42 AM IST
Nifty Outlook

We had a pathetic start for the week on Monday as Nifty surprisingly opened with a massive cut of more than 200 points as indicated by the SGX Nifty. This was mainly on the back of mounting concerns over the Covid-19 cases on the domestic front. Since it weighed down heavily on the financial space, the knock turned out to be a brutal one. In this process, the Nifty went on to tumble over 500 points to test the sub-14,300 territory. Things looked extremely scary at the close on the opening day; but fortunately there was no follow through seen to it. In fact, throughout the remaining part of the week, we managed to recover fair bit of ground to trim major portion of losses.

Since the last couple of weeks, market was trapped in a small range where it neither had strength to stay beyond 14,900 nor it was letting it slide below 14,500. Due to Monday’s sharp selloff, Nifty breached this range in the downward direction and the major culprit of this was clearly the entire financial basket. Although, Nifty didn’t violate major support of 14,200, the BANKNIFTY finally slipped below its cluster of support placed at 32,400 – 32,200. Hence, till the time we do not see banking index crossing 32,500 – 33,000 levels, we are certainly not out of the woods yet. As far as Nifty is concerned, 14,700 – 14,850 remains to be a sturdy wall and surpassing it would really be a daunting task for the bulls. On the downside, 14,500 – 14,350 –
14,250 are the levels to watch out for.

If we have to take out any positives from the week gone by, then it would certainly be an overall improvement in the market breadth which remained strongly in favour of advances. Also there were few pockets like IT and Pharma did exceedingly well towards the latter half. But, we would like to highlight one point that the NIFTY MIDCAP50 index has confirmed a ‘Lower
Top Lower Bottom’ sequence on daily chart along with the breakdown from ‘Head and Shoulder’ pattern. Hence, identifying the apt theme and the potential movers within the same would prove out to be the key aspect. In our sense, it’s better to stay light on positions and avoid aggressive longs till the time few key levels are not reclaimed convincingly.

Stock recommendations:

NSE Scrip Code – STRIDES PHARMA

View – Bullish

Last close – Rs 922.15

Justification – The PHARMA seems to be in a different orbit altogether since the last 12 months. Mostly all counters from this space have completely compensated for the underperformance as well as boredom they had given for the previous five years. Now, stocks are in a hurry as the recent brief period of time as well as price correction got bought into. STRIDES PHARMA failed to participate in last few days’ rally; but on Friday, we finally witnessed a decisive price and volume breakout from the recent congestion zone. We recommend going long around 912 – 907 for a target of Rs 992 in coming days. The strict stop loss can be placed at Rs 872.

NSE Scrip Code – GRASIM

View – Bearish

Last close – Rs 1,353.20

Justification – Generally we do not associate this counter with the term ‘Sell’ or ‘Bearish’; because of its phenomenal run since the previous March lows. The stock price have given three-fold returns since then without even seeing a small phase of price correction. Although the higher degree trend remains strongly bullish, we are now seeing some signs of decent short
term correction in the stock. On the daily chart, we can see prices falling convincingly below ’20-EMA’ along with the bearish crossover of short term averages for the first time in last few months. We recommend selling on a small bounce for a target of Rs 1,270. The strict stop-loss can be placed at Rs 1,402.
Disclaimer: Sameet Chavan is Chief Analyst - Technical & Derivatives at Angel Broking. The analyst may have positions in one or more stocks. Views are personal.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :MarketsMarket technicalsNifty OutlookStrides PharmaGrasimstocks technical analysistechnical charts

Next Story